Biocon shares rise 2% after turning profitable in Q3
The company's revenue from operations increased by 34.4 percent to Rs 3,953.7 crore
Stay updated with breaking news from Harma Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The company's revenue from operations increased by 34.4 percent to Rs 3,953.7 crore
Anteris Technologies is a structural heart company delivering clinically superior and durable solutions through better science and better design.
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
CytoDyn Inc CEO Nader Pourhassan shared an update to its previously reported preliminary results from its Phase 1b/2 trials and compassionate use of...
In addition to Fragile X Syndrome, the gel is in clinical development in patients with refractory epilepsy, autism and 22q11.2 Deletion Syndrome